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Gastroesophageal reflux of varying severity is a common disorder for which
medical attention is sought at all levels, from pharmacists to specialist physi-
cians and surgeons. This briefoverview represents my current understanding of
reflux, its effects on the esophagus and my personal approach to treatment of
these disorders. Of necessity, because the literature is so extensive (a Medline
search on reflux from 1966 to 1993 yielded over 1500 papers.), I have relied in
places on the extensive review by Marks and Richter [1]. My paper emphasizes
the evaluation and treatment of patients with symptomatic reflux, esophagitis
and its complications. It describes why it is important to grade the disorders so
that the treatment used is appropriate to the severity of the disease. The more
severe the disease, the more specific the diagnostic information needed and the
more exacting the treatment. Various treatments and outcomes of therapy are
discussed, and a role for surgery is defined. The essence of effective medical
treatment of esophagitis is to reduce acidity of the refluxate to a level outside
the optimum proteolytic pH range ofpepsin, i.e., greater than pH 3.5.
INTRODUCTION
Gastroesophageal reflux is a physiological phenomenon in which gastric contents
enter the esophagus intermittently and are rapidly cleared. A complex and finely tuned
mechanism involving the lower esophageal sphincter (LES)b proper and the pinchcock
effect ofthe diaphragm must both accommodate the forward passage of swallowed mate-
rial (food, saliva) and prevent inappropriate or prolonged reflux from the stomach. The
lower esophageal sphincter mechanism must also allow gas or air in the stomach to
reflux, resulting in a belch, and at the same time, not permit acid liquid to do the same.
The reflux arc, arising from receptors in the gastric fundus surrounding the LES, whereby
the LES relaxes when confronted by gas and fails to do so for liquid or acid liquid, has
not been elucidated. A similar discrimination between air and liquid exists at the anal
sphincter. The inappropriate relaxation of a normal pressure LES is to be distinguished
from the incompetent (low pressure, i.e., < 10 mm Hg) sphincter, where reflux occurs by
gravity (e.g., by lying down or bending over) and by simple pressure differential between
the abdomen and the intrathoracic esophagus.
Massive reflux may reach the pharynx and can then gain access to the larynx and
lungs. Normal acid gastric contents refluxing into the esophagus are rapidly and efficient-
ly cleared through a combination ofreflex responses: propulsive orderly motility is initi-
ated to empty the esophagus of the bolus, the esophagus secretes neutralizing HC03- and
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an esophago-salivary reflex likewise initiates the flow ofHC03-rich saliva. It is not clear
whether these reflexes are operative during sleep, when salivary flow ceases. Nocturnal
acid reflux is presumably more damaging because ofthe loss ofsalivary neutralization.
Moreover, the esophageal squamous mucosa represents a tight epithelium that resists
penetration by H+, and probably, in part, under the influence of epidermal growth factor
secreted by the salivary glands, desquamated epithelium is replaced and damaged epithe-
lium repaired.
If this continuously balanced mechanism is disrupted by one or more changes in the
elements of the equation, esophagitis results; esophagitis, in turn, may have secondary
consequences. It is not known whether there is more than one initiating event, though it is
clear that acid and pepsin are the major sustaining factors in esophagitis. However, not all
reflux, much of which is physiological or very transient, results in esophagitis or even
produces symptoms. The threshold for these consequences has not been defined. In the
clinical context, we are only concerned with symptoms (heartburn or more rarely laryn-
go/pulmonary), with esophagitis and ultimately with the consequences ofesophagitis [1].
There are a number of circumstances in which an excess of acid/peptic contents
reflux into the esophagus. First, an excess of gastric contents may result from delayed
gastric emptying, which may be physiological due to a large fatty meal, or pathological as
in diabetic enteroneuropathy or other gastroparesis; the massive hypersecretion of
Zollinger-Ellison syndrome may also promote reflux, which is more damaging because
the refluxate is excessively acidic. Obesity, ascites and pregnancy promote reflux because
of increased abdominal pressure, the latter also reducing LES pressure by altered hor-
monal status. A low LES pressure is normally present in infants.
In some adults, the LES may be intrinsically weak (< 10 mm Hg), and in most such
cases, esophagitis results [1, 2]. However, this defect accounts for no more than 30 per-
cent of cases ofesophagitis [2]. The LES may be rendered incompetent by an axial hiatal
hernia, which often additionally functions as an intrathoracic reservoir of gastric contents
at the thoracic pressure, so that the esophagus is not fully cleared of acid. Hiatal hernia is
present in only half the cases ofesophagitis. The LES can also be damaged by operations,
such as a myotomy for achalasia. The reason why an LES with normal pressure relaxes
inappropriately is unknown. This functional defect accounts for many of the remaining
cases of reflux. Except in the ZE syndrome, esophagitis is not related to the level of acid
secretion [2], though deep reduction in acidity is the key to adequate esophagitis treat-
ment [3-6].
There are no good data defining the conditions necessary to induce esophagitis in
man. We do not know the necessary duration of exposure, the minimum composition of
the refluxate, nor whether the esophagus is more vulnerable at any particular time of day
or night. In experimental animals, acid without pepsin is much less ulcerogenic, and it
may be assumed that pepsin is as important in the genesis of esophagitis [7] as it is in its
continuance. This hypothesis is strongly supported by the efficacy ofomeprazole.
It may be presumed that the barrier-breaking agents, such as bile acids, may allow
the development of esophagitis, though with an intact stomach bile or alkaline reflux are
probably minor factors in the esophagus. Locally acting medications, such as tablets of
aspirin, quinaglute, tetracycline, ferrous sulfate and KCI among others, are more likely to
induce local ulceration rather than conventional "reflux" esophagitis [8], especially in
elderly patients with underlying motility disorders. Such lesions may also complicate
reflux esophagitis which would require independent treatment.
Disordered clearance in scleroderma prolongs the duration of acid reflux episodes,
and the same may apply after myotomy in the atonic esophagus ofachalasia.
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THE BASIS FOR THERAPY
Treatment requires an understanding of the specific causes of abnormal GE reflux,
the extent of the symptom or esophageal disease and the natural history of the disorder.
Goals for treatment must be defined so that therapy may be appropriately measured and
applied [1, 9, 10].
As many as 40 percent of adult Americans experience heartburn at least monthly,
according to a 1988 Gallup poll (cited by Richter [1, 9]). Though heartburn is the com-
monest symptom of esophagitis, as many as 70 percent of all persons with intermittent
heartburn do not have endoscopic evidence ofesophagitis [11], and only 61 percent of77
patients with persistent (daily) heartburn had esophagitis [12]. Overall in the U.S., there
is probably about a two percent prevalence ofesophagitis [13].
In the greater majority of cases, the occasional episode of heartburn may require no
treatment, or it may respond readily to antacids or to single doses of H2 antagonists.
Clearly, such patients do not require further diagnostic evaluation or treatment other than
simple symptomatic measures. For all patients with mild or intermittent heartburn,
change in habits commonly suffices [10], such as reducing the size ofmeals, especially if
the patient eats one heavy meal per day. For nocturnal heartburn, the patient should allow
three to four hr to elapse between the large evening meal and bedtime to permit time for
gastric emptying, avoid a bedtime snack and elevate the head of the bed. Other measures
include weight reduction especially if the patient is obese or if heartburn is related to
recent weight gain, avoidance of any foods causing reduced LES pressure (e.g., fats,
chocolate, coffee and alcohol), as well as medications that might promote reflux, such as
anticholinergics, calcium channel antagonists, progesterone, aminophylline or nitrates.
The role ofsmoking on reflux or healing is not clear [1]. Such simple measures may suf-
fice, and results can be readily assessed by the presence or absence of symptoms.
Assuming that the greater majority will have no or minimal esophagitis, the natural histo-
ry in such cases is very favorable. Thus, 50 percent of patients with Grade I disease will
remain unchanged, 45 percent will be healed and only five percent of all mild esophagitis
(i.e., Grade I) will have progressed to Grade III in three years [14].
In those patients with persistent heartburn, dysphagia, noncardiac chest pain or laryn-
go-pulmonary aspiration, further workup is necessary. Such workup should include a bar-
ium contrast radiographic examination (preferably with cine-fluoroscopy recording) to
confirm reflux and to size stricture ifpresent, as well as endoscopy to establish the degree
ofesophageal damage. Workup should also include 24-hr pH measurement and manome-
try to define LES pressure and esophageal contraction patterns, as indicated in patients
with unambiguous radiographic results, endoscopy or poor response to therapy and those
with atypical symptoms. In patients with concomitant duodenal or postgastrectomy ulcer,
serum gastrin should be measured to rule out Zollinger-Ellison syndrome.
The grading of esophagitis (see Refs. 1-4, 16, 23) is important, since Grade I
esophagitis has a very favorable outcome, seldom progressing to more advanced disease
and healing spontaneously in as many as 50 percent of cases [14]. Such cases may be
managed symptomatically with lifestyle changes and, where necessary, supplemented by
H2 receptor antagonists. Grade II esophagitis (linear erosions < 10 percent of the surface)
will heal well with H2 antagonists, pose no long-term risk to the patients and seldom
progress to more serious levels ofesophagitis. For many such patients, it may be enough
to control symptoms even though the relapse rate is fairly high [16-19]. Grades III and IV
(severe and/or complicated esophagitis) represent the hard core of the problem. The
majority of such cases have persistent or severe heartburn [12, 20, 21] or dysphagia
requiring treatment, and few, if any, remit spontaneously [1, 9, 11, 12, 20, 21]. A careful
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history of aspirin use should be taken in every patient with esophagitis, since aspirin may
contribute to esophagitis and delay healing [15]. Continuing esophagitis may progress to
stricture, and 10 or more percent are said to have Barrett's esophagus [11, 21, 22] (see
below). However, even severe esophagitis does not apparently affect survival [23].
PHARMACOLOGIC TREATMENT
Treatment of esophagitis prior to the advent of H2 antagonists with antacids alone or
combined with alginate was largely symptomatic [1, 10] and clinically useful only in
mild esophagitis or in patients with occasional heartburn and no esophagitis.
H2 antagonists were effective in treating duodenal ulcer, but results of treatment of
esophagitis were disappointing. At doses and duration of treatment similar to those for
duodenal ulcer, fewer than one third of esophagitis cases healed [5], and a majority of
controlled trials showed no benefit over placebo [1]. It was soon realized that the degree
of esophagitis determined response (see below). It was hoped that ranitidine, a more
potent acid suppressor than cimetidine (Figure 1), might be more effective than cimeti-
dine. However, ranitidine may have to be used at larger doses (e.g., 300 mg, four times
daily [18]), for longer periods, up to eight weeks, to heal esophagitis. Many patients are,
in fact, also resistant to ranitidine [3, 4, 16-18, 24, 25]. Such cases are not necessarily
hypersecretors [26]. Most cases resistant to H2 antagonists have severe esophagitis
(Grade III/IV) or stricture [26, 27]. While healing occurred in 78 percent of patients with
Grade II esophagitis at six weeks, Grades III and IV had healing rates of 38 percent and
23 percent, respectively [16]. Ranitidine at a dose of 150 mg per day was ineffective in
preventing relapse [16]. Similar data were obtained in other studies with ranitidine [18,
21, 25, 28] and other H2 antagonists, such as famotidine [17] or nizatidine (see Ref. 1).
The only H2 antagonist so far approved for esophageal reflux disease by the FDA is, in
fact, ranitidine. Limited data suggest that famotidine and nizatidine could be expected to
produce the same results.
OtherDrugs
Sucralfate has not been particularly effective in esophagitis [1].
Promotility drugs. (i) Bethanechol is of marginal benefit. (ii) Metoclopromide like-
wise is of marginal benefit and has the additional disadvantage of causing side effects in
almost 30 percent of patients, including fatigue, psychotropic changes, hirsutism and
extrapyramidal symptoms (tardive dyskinesia), which may persist [1]. (iii) Cisapride, a
newly released prokinetic agent, lacking the side effects of metoclopromide, increases the
LES pressure and improves esophageal and gastric propulsive motility. Cisapride appears
to be as effective in healing esophagitis as cimetidine or ranitidine (300 mg per day) and
apparently improves the benefit of H2 antagonists [1]. However, no comparison has been
made yet with omeprazole.
Proton pump inhibitors. Treatment of esophagitis, especially Grades III and IV,
remained unsatisfactory until the development of omeprazole, which provided for the first
time a means of suppressing acid output to a level not achievable in most cases with any
but extreme doses of H2 antagonists. Proton pump inhibitors, acting on the final step of
acid secretion, inhibit acid secretion more potently than the H2 antagonists, regardless of
stimulus, with the ability to raise the median pH of gastric contents to levels above 5.0
(Figure 1), whereas H2 antagonists only achieve median pH levels below 2.0 (Figure 1).
With the ability to so potently reduce acid, various studies have shown that the more
extreme acid reduction is necessary to heal esophagitis, especially esophagitis of more
severe grades [5, 6], most of which are resistant to H2 antagonist treatment [20-23]. The
degree to which acid reflux is diminishedby omeprazole at different doses [30] is reflected
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Figure 1. One likely explanation ofthe superior efficacy ofomeprazole over H2 antagonists for
the treatment of esophagitis may be the ability to keep gastric pH above the proteolytic opti-
mum for pepsin (from Ref. 35 with permission).
in some studies by improvement in healing rates and in the speed and extent of symptom
relief [1, 3-5, 24, 27]. Many cases, however, require up to two or more months to achieve
full healing [1, 4, 24], and 50 percent of Grade IV patients may be initially resistant to
omeprazole [4] due to a combination of inadequate acid suppression and impaired motili-
ty-dependent clearance of the esophagus detected by 24-hr pH recordings [27]. These
require higher doses and more prolonged courses of treatment. Most, if not all, such
patients require indefinite treatment with omeprazole.
Arguing from the knowledge that profound acid suppression is necessary for the
healing of esophagitis, especially that resistant to H2 antagonists, and that omeprazole
maintains gastric pH outside the pH optimum range ofpepsin (Figure 1), we may assume
that pepsin contributes to or is responsible for persistence of non-healing of esophagitis.
Moreover, while acid perfusion alone does not produce experimental esophagitis, the
addition of pepsin at physiological concentrations does promote the development of
lesions. Since basement membrane collagen is a specific substrate for pepsin, one might
postulate that pepsin is possibly a specific factor in the initiation as well as the mainte-
nance of esophagitis [7] and that omeprazole is so effective [3, 4, 24, 27, 30] precisely
and only because it renders pepsin ineffective [35]. Lansoprazole has a similar action and
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is as effective as omeprazole [31, 32] in suppressing acid secretion. It would, therefore,
be expected to have a similar therapeutic effect [1].
RELAPSE AND MAINTENANCE
When treatment is stopped, as many as 80 percent or more of severe esophagitis cas-
es relapse within six months ofhealing, induced by any method of treatment or any dose
ofomeprazole [4]. Ranitidine (150 mg, twice daily) did not prevent relapse in 90 percent
of cases healed on either omeprazole or ranitidine, compared to 33 percent relapse in 12
months on maintenance omeprazole (20 mg per day) [19]. Daily therapy is required for
effective maintenance [1], and in many cases, long-term, possibly life-long, treatment
with omeprazole is necessary.
Since relapse is almost universal, especially in Grade IIHIV esophagitis, surgery may
be a reasonable alternative to life-long omeprazole therapy [1, 9]. In the case of surgery,
the object is to prevent reflux. The cases most likely to benefit are those with incompe-
tent LES (pressure < 10 mm Hg), especially younger people with potential life-long
dependence on omeprazole and those with tracheopulmonary aspiration [9]. In these lat-
ter patients, omeprazole may reduce the volume and acidity of the gastric contents, but it
does not alter reflux mechanisms nor the frequency ofreflux [ 4].
Chronic use of aspirin or other non-steroidal anti-inflammatory drugs may promote
esophagitis or contribute to resistance to therapy or relapse of esophagitis [15].
Mechanisms of these effects have not yet been fully evaluated. Certainly, non-steroidal
anti-inflammatory drugs should be proscribed before considering surgery.
COMPLICATIONS
Stricture
Esophageal stricture may be broadly divided into two categories: those associated
with or resulting from reflux esophagitis and those due to local action of a variety ofpills
[8]. Stricture is not the inevitable result of reflux, but some patients have a distinct ten-
dency to stricture, requiring repeated dilatations. Dysphagia predominates and is always
present when the lumen diameter is smaller than 12 mm. Heartburn may long precede
dysphagia but often ameliorates or disappears with the onset of dysphagia [1]. In such
patients, the majority have at least Grade II esophagitis, which is generally resistant to
treatment with H2 antagonists, even though acid secretion is not different from controls
with esophagitis but without stricture [26]. In such patients, treatment with dilatation is
much more effective when combined with adequate long-term acid suppression by
omeprazole [22]. With this approach, surgery is seldom required.
In patients with severe grades of esophagitis, the presence of a stricture is a marker
for resistance to therapy and for high rates ofrelapse [26], so that intensive and long-term
acid-suppressing therapy with omeprazole combined with esophageal dilatation is indi-
cated [4, 22]. Antireflux surgery is usually successful as well [1] but should be delayed
until the esophagitis is healed by omeprazole.
The second group ofpatients, those with pill esophagitis, is generally older and may
or may not give a specific history of an episode of pill impaction. In the majority, the
onset is insidious, with dysphagia predominating. A number have pain, but few have
heartburn. The commonest medications involved are quinaglute, doxycyline/tetracycline,
potassium tablets, aspirin and ferrous sulfate, which cause acute injury when held up in
the esophagus [8]. This may occur because ofdysmotility (especially in the elderly), as a
result of swallowing in the horizontal posture or because of the presence of a Schatzki
ring or reflux stricture. Such lesions may then set up enough inflammation or local spasm
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to trap future tablets and so perpetuate a vicious cycle. These cases ofstricture are treated
by avoidance of the offending medication and dilatation until healed, and they may
require local injection of steroids to promote healing. In the absence of reflux (e.g., with
mid-esophageal location ofstricture), acid suppression is not needed.
Barrett's Esophagus.
In five to twelve percent of patients with symptomatic reflux undergoing endoscopy,
the distal esophagus may be found to be lined with columnar epithelium, so-called
Barrett's esophagus. This condition may be present in young children, raising the possi-
bility that it is a congenital disorder. In adult life, it occurs mostly in age 40-80, more
commonly (65-80 percent) in white males and is considered to be the consequence of ero-
sive esophagitis. The importance of this condition is that when the epithelium is of a spe-
cialized columnar intestinal type, it carries the potential for malignant transformation to
adenocarcinoma [1, 35]. Gastric fundic or junctional epithelium apparently carries no
malignant potential, as opposed to intestinal type epithelium. Thus, histologic classifica-
tion is important in planning surveillance studies [33].
The other significant aspect to Barrett's epithelium is that it appears to be quite sus-
ceptible to reflux damage, frequently presenting with severe grades of esophagitis, frank
localized "peptic" ulcer and stricture [22, 33]. There is no indication that these lesions
heal more slowly because of the columnar lining [33]. In healing, the epithelium is again
covered by the same columnar cells. There is no evidence that the area ofcolumnar meta-
plasia can be influenced by treatment with acid suppression or elimination of abnormal
reflux by surgery. There is also no evidence yet whether effective treatment of the super-
imposed esophagitis influences the malignant transformation. The whole complex story
ofBarrett's esophagus is unfolding at the present time [33]. Questions regarding etiology,
natural history, neoplastic transformation and treatment remain incomplete.
COST AND QUALITY OF TREATMENT
Omeprazole is clearly superior to any other medical therapy [1, 19, 25, 27-30].
Because of the high cost of omeprazole (20 mg/day costs $1150/year), various analyses
of the cost of alternative treatments have been made. One such study [34] (supported by
Merck, Sharp & Dohme) concludes that omeprazole is the most cost-effective treatment
in patients in whom conservative (lifestyle) treatment, so-called Plan 1 [10], fails to
relieve persistent reflux symptoms. In young persons, antireflux surgery, where indicated,
may be preferable, especially if, as it appears, laparoscopic techniques reduce risk and
morbidity. For those with reflux and laryngobronchial aspiration not relieved by omepra-
zole, surgery is indicated.
CONCLUSION
Pharmacologic treatment of reflux esophagitis and its symptoms clearly depends on
the adequate suppression of gastric acidity. The threshold for effective treatment appears
to be an increase in gastric juice pH to levels outside the optimum for pepsin [35].
Omeprazole (and lansoprazole) inhibitors of the proton pump, but not H2 antagonists at
any reasonable dose, achieves a median pH > 5, with 85 percent of samples above pH
4.0. The optimum pH for pepsin is below 3.5. Thus, as shown in Figure 1, proton pump
inhihibitors achieve such apH profile, while H2 antagonists do not. This concept provides
a useful marker for therapeutic effectiveness, which has been determined from results of
clinical trials. Until we understand the determinants of susceptibility to mucosal ulcera-
tion, acid suppression remains the mainstay oftherapy.
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